Haleon/$HLN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Haleon

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Ticker

$HLN
Sector

Primary listing

NYSE

Employees

24,561

Haleon Metrics

BasicAdvanced
$45B
44.12
$0.22
0.22
$0.18
2.52%

What the Analysts think about Haleon

Analyst ratings (Buy, Hold, Sell) for Haleon stock.

Bulls say / Bears say

Haleon projects high single-digit adjusted operating profit growth starting in 2026, supported by stable demand in core markets and planned supply chain cost reductions, targeting productivity savings of £800 million over five years and cutting working capital by 30% annually to boost cash flow (Reuters)
In April 2025, Haleon acquired the remaining 12% of its Tianjin TSKF Chinese joint venture for ¥1.62 billion, making it a wholly owned subsidiary and gaining added strategic flexibility in a business that represents about 40% of its China revenues (Reuters)
Despite top-line pressures, Haleon’s adjusted operating profit for H1 2025 was £1.24 billion, above analyst expectations of £1.22 billion, showing strong margin gains from pricing actions and cost efficiencies (Reuters)
Haleon lowered its full-year organic revenue growth outlook to about 3.5% from the previous 4%–6%, after reporting H1 2025 organic growth of 3%, short of analysts’ 3.3% expectation (Reuters)
Weak consumer confidence and retailer inventory reductions in North America—Haleon’s biggest market—weighed on H1 2025 organic revenue growth at 3.2%, below the 3.4% analysts expected, highlighting ongoing U.S. challenges (Reuters)
After the revised outlook, Haleon’s shares fell by as much as 5% on July 31, 2025, reflecting investor doubts about the company’s ability to overcome its short-term growth hurdles (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Haleon Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Haleon Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HLN

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

Sept18
Haleon
DividendPayment
$0.058542Per share
FAQs